Synthesis, biological evaluation, and SAR studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives: ligands with mixed NOP and opioid receptor profile
Authors
Kumar, VinodPolgar, Willma E.
Cami-Kobeci, Gerta
Thomas, Mark P.
Khroyan, Taline V.
Toll, Lawrence
Husbands, Stephen M.
Affiliation
Central University of PunjabSRI International
University of Bath
Florida Atlantic University
Issue Date
2018-09-19Subjects
ORL-1analgesics
Kappa opioid receptor
Mu opioid receptors
Nociceptin
opioid
Subject Categories::B210 Pharmacology
Metadata
Show full item recordAbstract
A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and delta (DOP) opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. The majority of the new ligands displayed high binding affinities for the three opioid receptors, and moderate affinity for NOP receptors. The affinities for NOP receptors are of particular interest as most classical opioid ligands do not bind to NOP receptors. The predominant activity in the [35S]GTPγS assay was partial agonism at each receptor. The results are consistent with our prediction that an appropriate 14β side chain would access a binding site within the NOP receptor and result in substantially higher affinity than displayed by the parent compound naltrexone. Molecular modeling studies, utilizing the recently reported structure of the NOP receptor, are also consistent with this interpretation.Citation
Kumar V, Polgar Wi, Cami-Kobeci G, Thomas MP, Khroyan TV, Toll L, Husbands SM (2018) 'Synthesis, biological evaluation, and SAR studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives: ligands with mixed NOP and opioid receptor profile', Frontiers in Psychiatry, 9, 430Publisher
FrontiersJournal
Frontiers in PsychiatryPubMed ID
30283364Additional Links
https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00430/fullType
ArticleLanguage
enISSN
1664-0640EISSN
1664-0640Sponsors
This work was funded by the National Institutes of Health National Institute on Drug Abuse grants DA20469 and DA07315 (SH) and DA023281 (LT). MT was supported by the Wellcome Trust (Programme Grant 082837 to BVL Potter, University of Bath).ae974a485f413a2113503eed53cd6c53
10.3389/fpsyt.2018.00430
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
- Authors: Zaveri NT, Journigan VB, Polgar WE
- Issue date: 2015 Apr 15
- Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
- Authors: Tzschentke TM, Rutten K
- Issue date: 2018 Feb
- Pharmacogenomic study of the role of the nociceptin/orphanin FQ receptor and opioid receptors in diabetic hyperalgesia.
- Authors: Rutten K, Tzschentke TM, Koch T, Schiene K, Christoph T
- Issue date: 2014 Oct 15
- Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
- Authors: Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L
- Issue date: 2009 Dec
- Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
- Authors: Journigan VB, Polgar WE, Khroyan TV, Zaveri NT
- Issue date: 2014 Apr 15